Pamela J Burgess

Array ( [id] => 14743989 [patent_doc_number] => 20190255168 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-22 [patent_title] => CHIMERIC DENGUE VIRUS E GLYCOPROTEINS COMPRISING MUTANT DOMAIN I AND DOMAIN II HINGE REGIONS [patent_app_type] => utility [patent_app_number] => 16/146996 [patent_app_country] => US [patent_app_date] => 2018-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19555 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16146996 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17287077 [patent_doc_number] => 11203617 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-12-21 [patent_title] => Immunogenic trimers [patent_app_type] => utility [patent_app_number] => 16/139173 [patent_app_country] => US [patent_app_date] => 2018-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 42 [patent_figures_cnt] => 43 [patent_no_of_words] => 34121 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 100 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16139173 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14072397 [patent_doc_number] => 20190085086 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-21 [patent_title] => SCREENING METHODS FOR IDENTIFYING AND TREATING HIV-1 INFECTED PATIENT SUB-POPULATIONS SUITABLE FOR LONG TERM ANTI-CCR5 AGENT THERAPY [patent_app_type] => utility [patent_app_number] => 16/134658 [patent_app_country] => US [patent_app_date] => 2018-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23541 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16134658 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16156573 [patent_doc_number] => 20200216519 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-09 [patent_title] => DNA ANTIBODY CONSTRUCTS FOR USE AGAINST EBOLA VIRUS [patent_app_type] => utility [patent_app_number] => 16/647082 [patent_app_country] => US [patent_app_date] => 2018-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40945 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16647082 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14069465 [patent_doc_number] => 20190083620 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-21 [patent_title] => METHODS FOR INDUCING AN IMMUNE RESPONSE AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN SUBJECTS UNDERGOING ANTIRETROVIRAL TREATMENT [patent_app_type] => utility [patent_app_number] => 16/132555 [patent_app_country] => US [patent_app_date] => 2018-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18801 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 142 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16132555 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16297774 [patent_doc_number] => 20200283497 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-10 [patent_title] => RNA REPLICON FOR EXPRESSING AT CELL RECEPTOR OR AN ARTIFICIAL T CELL RECEPTOR [patent_app_type] => utility [patent_app_number] => 16/645757 [patent_app_country] => US [patent_app_date] => 2018-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 57809 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16645757 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17351047 [patent_doc_number] => 11225673 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-01-18 [patent_title] => Stable recombinant MVA vectors comprising modified RSV genes with reduced intramolecular recombinatorial activity [patent_app_type] => utility [patent_app_number] => 16/124274 [patent_app_country] => US [patent_app_date] => 2018-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 34 [patent_no_of_words] => 10878 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 137 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16124274 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16512930 [patent_doc_number] => 20200392188 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-17 [patent_title] => MARBURG VIRUS VACCINE WITH HUMAN REPLICATION-DEFICIENT ADENOVIRUS AS VECTOR [patent_app_type] => utility [patent_app_number] => 16/756610 [patent_app_country] => US [patent_app_date] => 2018-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7009 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16756610 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16976232 [patent_doc_number] => 20210220469 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-22 [patent_title] => Immuno-Oncology Compositions and Methods for Use Thereof [patent_app_type] => utility [patent_app_number] => 16/641728 [patent_app_country] => US [patent_app_date] => 2018-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20122 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16641728 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19368492 [patent_doc_number] => 12060566 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-08-13 [patent_title] => Self-inactivating lentiviral vector comprising a FOXP3 expression cassette [patent_app_type] => utility [patent_app_number] => 16/640306 [patent_app_country] => US [patent_app_date] => 2018-08-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 19 [patent_no_of_words] => 19157 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16640306 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16519472 [patent_doc_number] => 10870682 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-12-22 [patent_title] => Methods and compositions for dengue virus vaccines [patent_app_type] => utility [patent_app_number] => 16/105346 [patent_app_country] => US [patent_app_date] => 2018-08-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 9 [patent_no_of_words] => 10574 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 121 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16105346 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16009379 [patent_doc_number] => 20200179532 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-11 [patent_title] => NANOPARTICLE PLATFORM FOR ANTIBODY AND VACCINE DELIVERY [patent_app_type] => utility [patent_app_number] => 16/636141 [patent_app_country] => US [patent_app_date] => 2018-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23445 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -56 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16636141 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16406752 [patent_doc_number] => 10815295 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-10-27 [patent_title] => Broadly neutralizing HIV-1 antibodies that bind to the CD4-binding site of the envelope protein [patent_app_type] => utility [patent_app_number] => 16/044083 [patent_app_country] => US [patent_app_date] => 2018-07-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 87 [patent_figures_cnt] => 88 [patent_no_of_words] => 66555 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 254 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16044083 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13837455 [patent_doc_number] => 20190022212 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-24 [patent_title] => METHODS FOR SAFE INDUCTION OF CROSS-CLADE IMMUNITY AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN HUMAN [patent_app_type] => utility [patent_app_number] => 16/041167 [patent_app_country] => US [patent_app_date] => 2018-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23665 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 309 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16041167 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13840521 [patent_doc_number] => 20190023745 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-24 [patent_title] => METHODS AND COMPOSITIONS FOR ZIKA VIRUS VACCINES [patent_app_type] => utility [patent_app_number] => 16/040267 [patent_app_country] => US [patent_app_date] => 2018-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38400 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16040267 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13840519 [patent_doc_number] => 20190023744 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-24 [patent_title] => TRIMER STABILIZING HIV ENVELOPE PROTEIN MUTATIONS [patent_app_type] => utility [patent_app_number] => 16/039860 [patent_app_country] => US [patent_app_date] => 2018-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31192 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16039860 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15990541 [patent_doc_number] => 20200171141 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-04 [patent_title] => Compositions and Methods for Generating an Immune Response to LASV [patent_app_type] => utility [patent_app_number] => 16/631489 [patent_app_country] => US [patent_app_date] => 2018-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17746 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16631489 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16108639 [patent_doc_number] => 20200206342 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-02 [patent_title] => ENGINEERED VARIANTS OF HIV-1 ENV FOR PRESENTATION OF QUARTENARY EPITOPES [patent_app_type] => utility [patent_app_number] => 16/631275 [patent_app_country] => US [patent_app_date] => 2018-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32019 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16631275 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13871343 [patent_doc_number] => 20190032012 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-31 [patent_title] => METHODS AND COMPOSITIONS FOR SUPPRESSING RETROVIRUSES [patent_app_type] => utility [patent_app_number] => 16/036659 [patent_app_country] => US [patent_app_date] => 2018-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4284 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16036659 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14852185 [patent_doc_number] => 10414804 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-09-17 [patent_title] => Method of inducing an immune response by administering exosomes comprising Nef-fusion proteins [patent_app_type] => utility [patent_app_number] => 16/034237 [patent_app_country] => US [patent_app_date] => 2018-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 25 [patent_no_of_words] => 13487 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16034237 [rel_patent_id] =>[rel_patent_doc_number] =>)